Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Meta Expands AI Training With Employee Activity Tracking Tools 
SOUTH SAN FRANCISCO, Calif., March 01, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the management team are scheduled to present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 10:40 a.m. EST. The conference is being held March 7-9, 2016, at the Marriott Copley Place in Boston.
Presenting are Tassos Gianakakos, chief executive officer, and Dr. Jonathan C. Fox, M.D., Ph.D., chief medical officer.
To access the live webcast of MyoKardia’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK- 461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition. For more information, please visit www.myokardia.com.
Media Contact: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected] Investor Contact: Matt Clawson Pure Communications, Inc. 949-370-8500 [email protected]
